What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Her primary areas of investigation include Internal medicine, Pharmacology, Pharmacokinetics, Gastroenterology and Pembrolizumab.
Her Internal medicine research incorporates elements of Surgery, Melanoma, Oncology and Monoclonal.
She combines subjects such as Protein kinase B, Chemotherapy, Toxicity, Nausea and MK-2206 with her study of Pharmacology.
Her Pharmacokinetics research is multidisciplinary, incorporating elements of Tolerability and Immunology.
Her work investigates the relationship between Gastroenterology and topics such as Neutropenia that intersect with problems in Taxane and Cabazitaxel.
In her study, Carcinoma is inextricably linked to Lung cancer, which falls within the broad field of Pembrolizumab.
Her most cited work include:
- Pembrolizumab for the treatment of non-small cell lung cancer (3324 citations)
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2625 citations)
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial (1256 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Internal medicine, Pharmacology, Pharmacokinetics, Oncology and In patient.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery.
The various areas that Amita Patnaik examines in her Pharmacology study include Neutropenia, Monoclonal antibody, Docetaxel and Dose escalation.
The Pharmacokinetics study combines topics in areas such as Nausea, Tolerability and Toxicity.
Her studies deal with areas such as Clinical trial, Cohort, Pathology, Chemotherapy and Carboplatin as well as Oncology.
Her research in Pembrolizumab tackles topics such as Melanoma which are related to areas like Ipilimumab.
She most often published in these fields:
- Internal medicine (47.16%)
- Pharmacology (41.94%)
- Pharmacokinetics (37.68%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (47.16%)
- Oncology (31.28%)
- Cancer research (21.56%)
In recent papers she was focusing on the following fields of study:
Internal medicine, Oncology, Cancer research, Cancer and In patient are her primary areas of study.
Her research related to Adverse effect, Pembrolizumab, Pharmacokinetics, Tolerability and Nausea might be considered part of Internal medicine.
Her studies in Adverse effect integrate themes in fields like Gastroenterology, MEK inhibitor, Pneumonitis, Toxicity and Rash.
The study incorporates disciplines such as Carboplatin, Pemetrexed, Overall survival, Lung cancer and Antitumor activity in addition to Pembrolizumab.
Pharmacokinetics is a subfield of Pharmacology that she studies.
Amita Patnaik has researched Oncology in several fields, including Clinical trial, Chemotherapy, Melanoma, Hazard ratio and Cohort.
Between 2017 and 2021, her most popular works were:
- Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study (238 citations)
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (200 citations)
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. (111 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Amita Patnaik spends much of her time researching Internal medicine, Oncology, Pembrolizumab, Adverse effect and Pharmacokinetics.
Her Clinical trial, Nausea, Advanced melanoma and Discontinuation study are her primary interests in Internal medicine.
Her research on Nausea also deals with topics like
- Vomiting together with Pharmacodynamics, Gastroenterology, Drug and Lymphoma,
- Bevacizumab most often made with reference to Cohort.
Amita Patnaik has included themes like Cancer, Combination therapy and Hazard ratio in her Oncology study.
Her research in Pembrolizumab intersects with topics in Carboplatin, Pemetrexed, Overall survival, Melanoma and Lung cancer.
Her study focuses on the intersection of Pharmacokinetics and fields such as Toxicity with connections in the field of Colorectal cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
